Novadip Biosciences

Novadip Biosciences develops a new class of regenerative tissue products designed to accelerate the healing of large bone defects, bone non-union, and spine fusion in a single treatment. The company's pipeline, including NVD-003 and NVD-X3, targets patients with critical size bone defects, trauma, spinal problems, and rare conditions like Congenital Pseudarthrosis of Tibia (CPT). Their technology aims to provide an alternative to amputation and permanent loss of mobility for patients who do not heal properly due to factors like diabetes or obesity.